Psoriasis: Zulassung für selektiven IL-23-Hemmer
Crossref DOI link: https://doi.org/10.1007/s15012-018-2648-2
Published Online: 2018-01-22
Published Print: 2018-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
red,
